Skip to main content
. 2021 May 26;9:38. doi: 10.1186/s40364-021-00294-9

Fig. 3.

Fig. 3

Schematic overview of the development of novel immune cell-based engager antibodies 1) Half-life extended-bispecific T cell engager (HLE-BiTE) 2) Checkpoint inhibitory T cell-engaging (CiTE) 3) Simultaneous multiple interaction T-cell engaging (SMiTE) 4) Secreted BiTE (eg. CAR.BiTE, OVs-armed BiTE) 5) T cell engager with silenced Fc domain 6) Multivalent T cell engager 7) Multi-specific T cell engager 8) Innate or innate-like cell engager CAR: chimeric antigen receptor OVs: Oncolytic viruses